NCT00918528Unknown1 期
Effect of Mitomycin C on Urethral Stricture Recurrence After Internal Urethrotomy
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 试验地点
- 1
- 主要终点
- Urethral stricture recurrence
研究概览
简要总结
The aim of this study is to evaluate the efficacy of local injected mitomycin C at the time of internal urethrotomy in order to prevent the recurrence of urethral strictures.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Male urethral stricture suitable for internal urethrotomy
- •Stricture length less than 10 mm
排除标准
- •Stricture length over 10 mm
- •Benign prostate enlargement
研究组 & 干预措施
1. Internal urethrotomy
Active Comparator
干预措施: Internal urethrotomy (Procedure)
2. Internal urethrotomy + mitomycin C
Experimental
干预措施: Internal urethrotomy (Procedure)
2. Internal urethrotomy + mitomycin C
Experimental
干预措施: Mitomycin C - local injection (Drug)
结局指标
主要结局
Urethral stricture recurrence
时间窗: One year
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Effect of a SI-MMC on the IVR Rate After Ureteroscopy for UTUCUpper Urinary Tract CarcinomaNCT05731622Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)100
已完成
2 期
Trial of Mitomycin C During Nephroureterectomy for Urothelial CarcinomaUrothelial CarcinomaNCT03658304University of Florida29
已完成
3 期
Mytomycin intravesical instillation soon after nephroureterectomyRenal pelvic cancer, ureteral cancerUpper urinary tract carcinomaJPRN-jRCTs011180027Hori Jun-ichi15
已完成
不适用
Effect of Mitomycin C in intra-operative and post-operative in recurrent, visual acuity and intraocular pressure after pterygium surgeryPterygium.PterygiumIRCT201207037466N3Arak University of Medical Sciences, Deputy of Education ad research120
已完成
不适用
Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC PatientsUrinary Bladder NeoplasmsUrologic NeoplasmsNeoplasmsUrinary Bladder DiseasesUrologic DiseasesNCT02891460UroGen Pharma Ltd.18